SQLite Web: event_store.db

Update row 39590 in events

seq

Primary key. INTEGER

id

TEXT NOT NULL

kind

TEXT NOT NULL

ts

TEXT NOT NULL

actor

TEXT

subject_entity_ids

TEXT

payload

{"created_at":"2026-04-14T02:04:49.876253+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:5e53f3c01e3e2063","evidence_event_ids":["evt_925230b065b2"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/2007191/0002007191-26-000017.txt","as_of":"2026-04-14T02:04:49.876253+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/2007191/0002007191-26-000017.txt","company":"Telix Pharmaceuticals Ltd","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/2007191/0002007191-26-000017.txt","article_chars":1385,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_63f21fd4c3b57add","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/2007191/0002007191-26-000017.txt","content_type":"text/plain","enriched_at":"2026-04-14T02:22:25.188371+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/2007191/0002007191-26-000017.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/2007191/0002007191-26-000017.txt","source_event_id":"evt_925230b065b2","source_quality":"medium","status_code":200,"version":"signal_enrichment_v2"},"form_type":"6-K","fp":"51ddb30dfacd577a","kind":"sec_filing","published_at":"20260413","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.72,"dates_mentioned":["2026-04-13","2026-04-14","April 2026"],"entities":[{"asset_class":"equity","name":"Telix Pharmaceuticals Limited","relevance":"high","symbol":"","type":"issuer"},{"asset_class":"equity","name":"Regeneron","relevance":"high","symbol":"","type":"counterparty"},{"asset_class":"other","name":"Australian Securities Exchange","relevance":"medium","symbol":"","type":"exchange"},{"asset_class":"other","name":"U.S. Securities and Exchange Commission","relevance":"medium","symbol":"","type":"regulator"}],"event_type":"listing","information_gaps":["The cleaned text does not include the contents of Exhibit 99.1 (the actual collaboration details), so specific business/financial implications are not disclosed here.","No explicit guidance, revenue/earnings impact, timelines, or financial figures are provided in the provided text.","The signal type is described as discovery_sec_filing_delta, but no prior known state or comparison details are included in the provided text."],"key_facts":["Filing is a Form 6-K for Telix Pharmaceuticals Limited (foreign private issuer).","The Form 6-K states that on April 13, 2026 (Melbourne, Australia), Telix filed an announcement with the Australian Securities Exchange titled \u201cTelix and Regeneron Announce Radiopharma Collaboration.\u201d","A copy of the ASX announcement is attached to the Form 6-K as Exhibit 99.1.","The Form 6-K states that the information contained in the Form 6-K, except for commentary in Exhibit 99.1 appearing in the third, fourth and fifth paragraphs on page 1, is incorporated by reference into Telix\u2019s Registration Statement on Form F-3ASR (File No. 333-293611) and Registration Statement on Form S-8 (File No. 333-283917).","The filing includes a signature section indicating the report was signed on behalf of the registrant."],"numeric_claims":[],"primary_claim":"On April 13, 2026, Telix Pharmaceuticals Limited filed an ASX announcement titled \u201cTelix and Regeneron Announce Radiopharma Collaboration\u201d as Exhibit 99.1 to its Form 6-K.","relevance_score":0.45,"sentiment":"neutral","source_quality":"medium","summary":"Telix Pharmaceuticals Ltd filed a Form 6-K on April 13, 2026, attaching an ASX announcement titled \u201cTelix and Regeneron Announce Radiopharma Collaboration.\u201d The filing indicates most content is incorporated by reference into specified registration statements.","topics":["SEC filing","Form 6-K","Exhibit 99.1","ASX announcement","radiopharma collaboration","incorporation by reference"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 6-K \u00b7 Telix Pharmaceuticals Ltd \u00b7 Filed 20260413","ticker":"TLX","tickers":["TLX"],"title":"TLX filed 6-K","url":"https://www.sec.gov/Archives/edgar/data/2007191/0002007191-26-000017.txt"}}

TEXT NOT NULL

source_ref

TEXT

confidence

REAL (default 0.0

dedupe_key

TEXT

episode_id

TEXT

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel